A5007119843- HIV, Drug Use, Sexual Risk
- Hepatitis C virus research
- Opioid Use Disorder Treatment
- HIV/AIDS Research and Interventions
- Hepatitis B Virus Studies
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
- Liver Disease Diagnosis and Treatment
- Alcohol Consumption and Health Effects
- Clostridium difficile and Clostridium perfringens research
- Bacillus and Francisella bacterial research
- SARS-CoV-2 detection and testing
- Forensic Toxicology and Drug Analysis
- Cannabis and Cannabinoid Research
- Blood donation and transfusion practices
- COVID-19 epidemiological studies
- Sex work and related issues
- Bacterial Identification and Susceptibility Testing
- Vaccine Coverage and Hesitancy
- Data-Driven Disease Surveillance
- Drug-Induced Hepatotoxicity and Protection
- Pharmacological Receptor Mechanisms and Effects
- Heparin-Induced Thrombocytopenia and Thrombosis
- Ectopic Pregnancy Diagnosis and Management
- HIV-related health complications and treatments
Glasgow Caledonian University
2013-2024
Public Health Scotland
2020-2024
National Health Service Scotland
2021
Health Protection Scotland
2011-2020
National Health Service
2018
Burnet Institute
2013
University of Bristol
2013
Monash University
2013
Kyushu University
2013
Special Olympics
2012
Background Government policy has precipitated recent changes in the provision of harm reduction interventions – injecting equipment (IEP) and opiate substitution therapy (OST) for people who inject drugs (PWID) Scotland. We sought to examine potential impact these on hepatitis C virus (HCV) transmission among PWID. Methods Findings used a framework triangulate different types evidence: 'group-level/ecological' 'individual-level'. Evidence was primarily generated from bio-behavioural...
Summary Sharing injecting paraphernalia (containers, filters and water) poses a risk of transmitting the hepatitis C virus ( HCV ). The prevalence of, from, such behaviour has not been extensively reported in E urope. People who inject drugs PWID ) were recruited cross‐sectional surveys from services providing sterile equipment across S cotland between 2008 2010. Participants completed questionnaire provided blood spot for anonymous testing. Logistic regression was used to examine...
Harm reduction has dramatically reduced HIV incidence among people who inject drugs (PWID). In Glasgow, Scotland, <10 infections/year have been diagnosed PWID since the mid-1990s. However, in 2015 a sharp rise diagnoses was noted PWID; many were subtype C with 2 identical drug-resistant mutations and some displayed low avidity, suggesting infections linked recent.We collected Scottish pol sequences identified closely related from public databases. Genetic linkage ascertained 228 Scottish,...
Hepatitis C virus (HCV) is the second largest contributor to liver disease in UK, with injecting drug use as main risk factor among estimated 200 000 people currently infected. Despite effective prevention interventions, chronic HCV prevalence remains around 40% who inject drugs (PWID). New direct-acting antiviral (DAA) therapies combine high cure rates (>90%) and short treatment duration (8 12 weeks). Theoretical mathematical modelling evidence suggests scale-up can prevent transmission...
Whilst injecting drugs in public places is considered a proxy for high risk behaviour among people who inject (PWID), studies quantifying its relationship with multiple drug-related harms are lacking and none have examined this the context of an ongoing HIV outbreak (located Glasgow, Scotland). We aimed to: 1) estimate prevalence Scotland associated factors; 2) association between HIV, current HCV, overdose, skin soft tissue infections (SSTI). Cross-sectional, bio-behavioural survey...
•HCV reinfection rates increased in the early phase of treatment scale-up with direct-acting antivirals among PWID Scotland.•Community-based pathways are reaching groups at high risk reinfection, regarded vital for elimination.•Low levels retesting HCV were observed beyond first year following successful treatment.•Considerable numbers reinfections may have gone undetected scale-up.•Concerted effort to ensure prompt diagnosis needs be integral national strategies PWID. Background &...
There has been little empirical evidence to show the 'real-world' impact of scaling-up direct-acting anti-viral (DAA) treatment among people who inject drugs (PWID) on hepatitis C virus (HCV) viraemia at a population level. We aimed assess rapid DAA scale-up PWID delivered through community services-including drug treatment, pharmacies, needle exchanges and prisons-in Tayside region Scotland, compared with Greater Glasgow Clyde (GGC) Rest Scotland (RoS).Natural experiment, evaluated using...
This is a protocol for Cochrane Review (Intervention). The objectives are as follows: To assess the impact of needle/syringe programmes with and without opiate substitution therapy (OST) on incidence HCV infection among people who inject drugs (PWID). effect OST alone PWID. Research questions How effective (NSP) use reducing PWID? does NSP vary according to duration treatment (i.e. NSPs weekly attendance versus monthly)? type service (fixed site mobile; high coverage low coverage)? dosage...
Since 2000 in the United Kingdom, infections caused by spore-forming bacteria have been associated with increasing illness and death among persons who inject drugs (PWID). To assess temporal geographic trends these illnesses (botulism, tetanus, Clostridium novyi infection, anthrax), we compared rates across England Scotland for 2000-2009. Overall, 295 were reported: 1.45 per 1,000 PWID 4.01 Scotland. The higher rate was mainly attributable to C. infection anthrax; of botulism tetanus...
Abstract Aims To estimate the impact of existing high‐coverage needle and syringe provision (HCNSP, defined as obtaining more than one sterile per injection reported) opioid substitution therapy (OST) on hepatitis C virus (HCV) transmission among people who inject drugs (PWID) in three UK settings to determine required scale‐up interventions, including HCV treatment, needed reach World Health Organization (WHO) target reducing incidence by 90% 2030. Design modelling using empirical estimates...